Lucid Diagnostics (NASDAQ:LUCD) Releases Earnings Results

Lucid Diagnostics (NASDAQ:LUCD) posted its quarterly earnings data on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, Yahoo Finance reports. The company had revenue of $1.04 million for the quarter. Lucid Diagnostics had a negative return on equity of 8,334.14% and a negative net margin of 2,169.07%. During the same period in the previous year, the business earned ($0.22) EPS.

Lucid Diagnostics Stock Performance

LUCD opened at $0.99 on Thursday. Lucid Diagnostics has a 12-month low of $0.97 and a 12-month high of $1.85. The stock has a 50-day moving average price of $1.29 and a 200-day moving average price of $1.34.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on LUCD shares. Cantor Fitzgerald reduced their price objective on shares of Lucid Diagnostics from $3.80 to $3.00 and set an “overweight” rating for the company in a research note on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $2.50 price target on shares of Lucid Diagnostics in a research report on Wednesday.

Hedge Funds Weigh In On Lucid Diagnostics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in Lucid Diagnostics in the fourth quarter worth $29,000. LPL Financial LLC bought a new position in shares of Lucid Diagnostics during the second quarter valued at $33,000. Bank of Montreal Can purchased a new stake in shares of Lucid Diagnostics during the 2nd quarter valued at about $35,000. BlackRock Inc. boosted its holdings in Lucid Diagnostics by 39.5% in the second quarter. BlackRock Inc. now owns 26,304 shares of the company’s stock worth $37,000 after purchasing an additional 7,448 shares during the last quarter. Finally, Citadel Advisors LLC lifted its holdings in shares of Lucid Diagnostics by 14.6% during the 3rd quarter. Citadel Advisors LLC now owns 35,333 shares of the company’s stock valued at $54,000 after buying an additional 4,506 shares during the period. 74.01% of the stock is currently owned by institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test.